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Abstract
Objective: The translocator protein (TSPO) has been implicated in numerous functions including steroid
production and regulation of stress and anxiety. Cannabinoids have been shown to reduce plasma testosterone
levels and alter anxiety levels. The aim of the present study was to determine whether the synthetic cannabinoid
HU210 is able to regulate TSPO expression in several peripheral organs.
Methods: HU210 (100 μg/kg) was administered intraperitoneally to both adult and adolescent male ratsfor 14
days. TSPO receptor expression in several organs, including the liver, spleen, kidneys and testes, was quantified by
membrane receptor binding using the selective radiolig and, PK11195. In cases where receptor binding data
indicated significant cannabinoid-induced differences, further RT-qPCR was carried out to determine the
transcriptional regulation of the TSPO gene. Additionally, film-autography was used to identify potential changes in
the spatial distribution of the TSPO tissue binding sites.
Results: Results indicate that HU210 induces significant reductions in testicular TSPO expression in adult but not
adolescent rats. No changes were found in other organs examined. These results are consistent with the previously
observed effects of cannabinoids on testosterone production and a presumed role for TSPO in steroidogenesis.
Conclusions: Overall, these results suggest that cannabinoids may alter testosterone production by altering the
expression of testicular TSPO and that the alteration of TSPO occurs in an age-dependent manner.
Keywords: Adolescent rats; Adult; Cannabinoid; Protein expression
Introduction
TSPO, previously known as the peripheral benzodiazepine receptor,
is a membrane bound protein found mainly on the outer
mitochondrial membrane [1]. Found in nearly all tissues, TSPO is
highly expressed in steroidogenic tissues such as the adrenals glands
and gonads [2]. A myriad of functions have been prescribed to TSPO
including cholesterol transport [3,4], steroidogenesis [4,5], stress
regulation [6], heme transport [7,8], cell proliferation [9,10], apoptosis
[11,12] and immunomodulation [13,14]. The protein sequence of
TSPO contains a cholesterol binding motif known as the CRAC
domain [15]. As such, best characterised function of TSPO is its ability
to associate with cholesterol [16] and assist in its transport across the
outer mitochondrial membrane, allowing the initiation of
steroidogenesis in the mitochondrial matrix [17,18]. Further, it has
been proposed that the transport of cholesterol across the
mitochondrial membranes is the rate-limiting step of steroidogenesis
[19]. As TSPO is important to the production of steroids, it has been
suggested to play a role in stress and anxiety regulation through the
regulation of neurosteroids [20-22]. Neurosteroids such as
allopregnanolone and dehydroepiandrosterone have been shown to
modulate GABAA receptors and thus affect stress and anxiety
responses [23-26]. The connection between TSPO and stress has also
been demonstrated in human and animal studies which have found a
reversible down regulation of TSPO expression in the blood and
peripheral organs in response to chronic stress or anxiety [6].
In males, the production of testosterone occurs primarily in the
testicular tissues. Both acute and chronic cannabinoid administration
have been shown to reduce testosterone production [27]. This effect
appears to be dose dependent [28] and has been well established in
both human and animal studies [29,30]. Cannabinoid administration
leads to dose-dependent reductions in gonadotropin-stimulated
testosterone production [28] but does not interfere with the binding of
gonadotropins to their receptors. This suggests that cannabinoids may
exert one of its effects locally by regulating steroidogenic pathways.
The precise mechanisms by which cannabinoids affect testosterone
production are unclear but may involve the inhibition of cholesterol
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esterase and ATPase dependent calcium transport [31,32]. More
recent studies involving CB1 knockout mice reveal that cannabinoids
are able to act on CB1 receptors on Leydig cells to reduce testosterone
production [33].
In addition to its ability to reduce testosterone production,
cannabinoids are also well known for their ability to induce euphoria,
relaxation and provide a psychological high [34]. Cannabinoid
administration has been observed to produce bidirectional effects on
stress and anxiety responses. Typically, lower doses have anxiolytic
effects and higher doses have anxiogenic effects [35]. Further,
differential responses in the adverse properties of cannabinoids have
been reported between adult and adolescent animals [36-38]
suggesting that adolescent animals experience greater residual
impairments and deficits. Similarly, differential responses to
cannabinoids between adult and adolescent animals have been found
in various neurotransmitter systems, including GABAergic,
serotonergic, dopaminergic and cannabinoid receptor systems [39-42].
Given the role of TSPO in steroidogenesis, and stress and anxiety
regulation, we examined the effect of a high-dose chronic
administration of HU210, a non-specific cannabinoid receptor
agonist, on TSPO expression. This effect was examined in both adult
and adolescent rats in testicular tissues as well as other peripheral
organs.
Methods
Ethics statement
All procedures involving animals were approved by the Animal
Care and Ethics Committee at the Australian Nuclear Science
Technology Organization.
Materials
HU210 was purchased from Sapphire Biosciences (Waterloo, NSW,
Australia). 3H-PK11195 was purchased from Perkin Elmer (Waltham,
MA, USA). TRIzol and RNA reverse transcription related reagents
were purchased from Invitrogen (Mulgrave, NSW, Australia). PCR
reagents were purchased from BioRad (Gladesville, NSW, Australia).
All other reagents unless specified were purchased from Sigma-
Aldrich (Castle Hill, NSW, Australia). Bicinchoninic acid protein assay
kit was purchased from Thermo Fisher Scientific (Scoresby, VIC,
Australia).
HU210 injection and tissue collection
Animals were housed in standard laboratory conditions, with food
and water supplied freely. Conditions were maintained at 22 ± 2°C, 60
± 10% humidity and a 12/12 light/dark cycle with lights on at 9 a.m
and off at 9 p.m. Animals were acclimatised for 1 week before HU210
or vehicle administration, during this time animals were also handled
daily to reduce the stress associated with intraperitoneal injections.
HU210 dose and treatment regime were adapted from Verdurand
et al. [41]. Briefly, twenty-four male Wistar rats, 12 adults and 12
adolescents, were used in this study. For each age group, animals were
randomly assigned into 2 groups: HU210 or vehicle treatment. All
animals were weighed daily prior to injection to ensure accurate
dosage. HU210 was dissolved in DMSO and tween and suspended in
saline in à 1:1:98 part solution. HU210 at 100 μg/kg, or vehicle was
injected at approximately 10:30 a.m. daily for 14 consecutive days.
Animals were restrained by hand and injected in the lower
intraperitoneal area into the intraperitoneal cavity. Adult and
adolescent animals were first injected on postnatal day (PND) 78 and
35 respectively and upon completion of HU210 or vehicle
administration were aged PND 91 and 48 respectively. Twenty-four
hours after the last injection, animals were euthanized by CO2
overdose and decapitated. Organs were swiftly collected, snap frozen
in liquid nitrogen and stored at -80°C until required.
Radioligand membrane binding
Organs were homogenised in approximately 50 mL of ice-cold TRIS
buffer (pH 7.4) and collected by centrifugation at 48000 g. This
procedure was then immediately repeated. Following the second
centrifugation, samples were resuspended in approximately 50
volumes of ice-cold TRIS buffer and stored at -80°C until required.
Protein concentration was measured using a bicinchoninic acid
protein assay kit following the manufacturer’s instructions.
Total binding was determined by 10 different concentrations of 3H-
PK11195 ranging from 1.26 nM to 40 nM. Non-specific binding was
determined by the addition of 5 µM PK11195 to replicate tubes
containing the 6 lowest concentrations of 3H-PK11195. Each tube
contained 60 µg of protein sample and the final reaction mixture was
400 µL. Each concentration of radioligand in both total and non-
specific binding was performed in triplicates. 3H-PK11195 bound
protein samples were incubated on ice for 90 minutes before
harvesting by rapid filtration through glass fibre Whatman GF/C
filters presoaked in 0.5% polyethyleneimine solution. Filters were
collected, placed in liquid scintillation cocktail and counted after
standing for at least 12 hours at room temperature. Non-specific
binding at the 4 highest concentrations was estimated by fitting a
linear equation to the experimentally obtained values for non-specific
binding. Bmax and Kd values were fitted by non-linear regression
using GraphPad Prism version 5.04 for Windows (Graph Pad
Software, San Diego, CA, USA).
RNA isolation and RT-Qpcr
Total RNA from testicular samples was isolated using TRIzol
reagent following manufacturer's instructions. RNA concentration was
determined using the Nanodrop 2000c spectrophotometer (Thermo
Fisher Scientific, Scoresby, VIC, Australia) and purity was assessed by
both 260/280 and 260/230 nm ratios. RNA quality was examined by
28S/18S ratios following electrophoresis on 1% agarose gel. First-
strand cDNA was synthesized by reverse transcription of 5 µg of RNA
using SuperScript III First-Strand Synthesis SuperMix following
manufacturer’s instructions. Following cDNA synthesis, samples were
diluted equally with DEPC treated water and stored at -20˚C until
required. cDNA was then amplified through real-time PCR by
CFX384 Real-Time PCR Detection System (Bio-Rad, CA, USA) using
SsoFast EvaGreen Supermix along with forward and reverse primers;
the total reaction volume was 5 µL. Primers for the TSPO [43], β-actin
[43] and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [44]
genes were used; PCR primer sequences for TSPO forward primer: 5’-
GGGAGCCTACTTTGTGCGTGG-3’; TSPO reverse primer: 5’-
CAGGTAAGGATACAGCAAGCGGG-3’; β-actin forward primer: 5’-
ACCAACTGGGACGATATGGAGAAGA-3’; β-actin reverse primer:
5’-CGCACGATTTCCCTCTCAGC-3’; GAPDH forward primer: 5'-
CCATGGAGAAGGCTGGGG-3’; and GAPDH reverse primer: 5'-
CAAAGTTGTCATGGATGACC-3’. PCR amplification run cycle
conditions were 98°C for 30 seconds and thermo-cycling for 40 cycles
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at 98°C for 5 seconds and 63°C for 10 seconds, with a final extension at
72°C for 10 minutes. To establish a melt curve, the temperature was
raised from 75°C to 95°C at 0.2°C increments. Melt curves with
multiple peaks which suggested contamination was discarded. The
quantitative PCR and relative expression of the TSPO gene was then
calculated using the CFX Manager Software, version 2.0 (Bio-rad, CA,
USA) using the “Normalized expression ∆∆Cq” option and both β-
actin and GAPDH as reference genes. All samples were performed in
triplicates. Of the 24 samples tested, 2 were excluded due to large gene
expression ratios between the GAPDH and β-actin housekeeping
genes.
Autoradiography
To assess changes in the spatial distribution of TSPO, snap-frozen
testicular tissues were sectioned at 20 µm in a cryostat, thaw mounted
on polylysine-coated slides and stored at -80°C until required. On the
day of the experiment, slides were thawed at room temperature and air
dried with a cool stream of air. Total binding was determined by
incubating slides with 1 nM of 3H-PK11195 in 130 mM TRIS-HCl
buffer for 20 minute at room temperature. Non-specific binding was
determined by incubating adjacent sections with 1 nM of 3H-PK11195
in the presence of 3 µM of PK11195. Following incubation, the slides
were briefly dipped twice in 130 mM TRIS-HCl buffer, washed twice
for 5 minutes in fresh 130 mM TRIS-HCl at room temperature. The
slides were briefly rinsed 3 times in chilled distilled H2O, dried under
a cool stream of air and allowed to be air dried overnight. Sections
were then exposed to Kodak BioMax MR film along with tritium
microscales with known activity concentrations in X-ray film cassettes.
Films were developed after 33 days; images were digitized using a
GS800 Calibrated Densitometer (Bio-Rad, CA, USA).
Statistical Analysis
Statistical analyses were performed by GraphPad Prism version 5.04
(La Jolla, CA, USA). Data were analysed with two-way ANOVA (age x
treatment) followed by multiple comparisons with Bonferroni
correction. Body weight data were analysed with two-way repeated
measures ANOVA. Significance was set at p < 0.05 and results are
presented as mean ± standard error of the mean.
Results
HU210 decreased body weight
Overall, analysis of weight data found significant group (F(3,432) =
4588, p < 0.0001), time (F(20,432) = 83.15, p<0.0001) and interaction
effects between the two variables (F(60,432) = 12.27, p<0.0001). After
arrival from the Animal Resources Centre and prior to HU210
treatment, the body weight of both adult and adolescent rats increased.
Multiple comparisons with Bonferonni correction found no significant
differences in adult or adolescent groups which were to receive either
HU210 or vehicle treatment prior to drug administration (p > 0.05 for
all time points prior to HU210 or vehicle administration; Figure 1).
Following the first injection of HU210 significant differences were
found between treatment groups in both adult and adolescent animals
in all time points following the first injection (p<0.01). After 14 days of
HU210 treatment both adult and adolescent groups displayed
significant reductions in body weight compared to their vehicle
controls (adult weight=361.56 ± 11.52 g vs 406.60 ± 9.10 g, p<0.001;
adolescent weight =225.42 ± 5.81 g vs 276.16±9.25 g, p<0.001; Figure
1). However, the dynamics of weight loss in both groups differed;
compared to pretreatment after 14 days of HU210 administration
adults lost 5.1% of body weight compared to a gain of 11.6% in vehicle
treated adults, while HU210 treated adolescents gained 38.6% of body
weight compared to gain of 70.0% in vehicle treated adolescents.
Further, adult animals experienced maximum weight loss on the
fourth day of HU210 treatment, whereas adolescent animals
experienced maximum weight loss on second day of HU210
treatment.
Figure 1: Effect of HU210 on body weight.
Change in the average body weight over time before and after
receiving HU210 (100 μg/kg i.p.) or vehicle over 14 days. HU210 had a
strong impact on body weight; differences between HU210 and vehicle
treated groups were significant for both adults and adolescent animals
for all time points following first injection (p < 0.01).
HU210 decreased 3H-PK11195 membrane binding in adult
testicular tissues
Total binding from radioligand membrane binding typically
reached a plateau at the 3 highest concentrations of 3H-PK11195 with
lower concentrations forming a rapid sharp curve towards the origin.
Non-specific binding displayed a near linear relationship with typical
r2>0.98. In testicular tissue, two-way ANOVA of Bmax revealed a
significant age effect (F (1,20)=16.72, p<0.01), a non-significant
treatment effect (F(1, 20)=2.71, NS) and a significant interaction effect
between the two variables (F(1, 20)=91.21, p<0.001). Overall,
compared to adults, adolescent testicular Bmax was lower by 54%
(8015.67 ± 464.52 vs 14822.5 ± 833.54 fmol/mg protein; Figure 2A).
Analysis of the interaction effect with multiple comparisons revealed
that HU210 treated adult animals had a significantly lower TSPO
Bmax compared to vehicle control (12778.33 ± 857.32 vs 16866.67 ±
806.61 fmol/mg protein; p<0.001; Figure 2A), this amounted to an
approximately 24% decrease in TSPO expression following HU210
treatment in adults. However, no significant differences were detected
between HU210 treated adolescent animals and their vehicle control
(7145.33 ± 573.91 vs 8886 ± 563.07 fmol/mg protein). Further, a two-
way ANOVA of Kd revealed a significant age effect (F(1, 20)=27.77,
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p<0.0001) with adult animals having a 52% higher Kd than adolescent
animals (8.09 ± 0.33 vs 4.18 ± 0.37; Figure 2B); no significant
treatment or interaction effect between the two variables were detected
(F(1,20)=1.17, NS; F(1,20)=2.48, NS, respectively). No significant age,
treatment or interaction effect in Bmax was seen in the kidney, spleen
or liver tissues (Figure 2C,2E,2G). Similarly no significant age,
treatment or interaction effect in Kd was seen in the kidney or spleen
tissues (Figure 2D and 2F). In the liver tissues, a significant age effect
was observed between adult and adolescent animals in Kd values
(Kd=2.15±0.26 vs 3.69±0.4, F(1,20)=11.03, p<0.01; Figure 2H); no
treatment or interaction effect was seen.
Figure 2: Radio ligand membrane binding results.
3H-PK11195 membrane binding results from HU210 and vehicle
treated adult and adolescent animals. Tissues examined include the A
and B) testes, C and D) kidneys, E and F) spleen and G and H) liver. In
testes, two-way ANOVA revealed a significant reduction in Bmax in
adolescent compared to adult animals (p < 0.0001). Multiple
comparisons revealed a significant reduction in Bmax in HU210
treated adults compared to control (p > 0.001), this was not seen in
adolescent animals. In both the testes and liver tissues a significant
difference in Kd between adult and adolescent animals was also found
(p < 0.0001, p < 0.01 respectively).
HU210 reduced testicular TSPO mRNA in HU210 treated
adult rats
Relative TSPO mRNA expression revealed a significant age
(F(1,18)=7.24, p<0.05), treatment (F(1,18)=6.99, p<0.05) and
interaction effect between the two variables (F(1,18)=7.01, p<0.05;
Figure 3). HU210 treated adult animals had a significantly reduced
TSPO mRNA expression compared to their vehicle controls (7.54 ±
2.36 vs 0.58 ± 0.02; p<0.01). This effect was not seen in adolescent
animals (0.64 ± 0.05 vs 0.59 ± .03; NS, Figure 3).
Figure 3: TSPO gene expression.
Normalized relative expression of the testicular TSPO mRNA as
determined by qPCR, using GAPDH and β-actin as housekeeping
genes. In adults, compared to vehicle control, HU210 treatment
significantly reduced TSPO mRNA expression (p<0.01). No significant
differences were observed between treatments in the adolescent group.
HU210 did not alter interstitial TSPO distribution within
testicular tissues
3H-PK11195 autoradiography of testicular tissues showed no
alterations in overall TSPO distribution in HU210 treated adults or
adolescent animals. TSPO distribution remained the highest in the
interstitial space (Figure 4), with distribution being roughly even
across the entire section. Non-specific 3H-PK11195 binding was very
low and close to unexposed film-autoradiographic background
indicating that observed 3H-PK11195 binding is specific and
represents TSPO. Since radioligand membrane binding was already
used to quantify the level of TSPO protein expression, the intensity of
the autoradiographic distribution was not measured as radioligand
membrane binding provides a more accurate measure of protein
expression.
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Figure 4: Autoradiographic distribution of TSPO expression.
Representative autoradiographs of testicular TSPO expression from
HU210 or vehicle treated adult and adolescent animals. A tritium
standard microscale, 4107 to 109 Bq/mg, is shown next to the images.
TSPO expression was determined by autoradiography using 3H-
PK11195. Compared to vehicle controls, no alterations to the site of
TSPO expression was found in HU210 treated animals; TSPO
expression remained high within the interstitial space.
Discussion
The main findings of this study are that in testicular tissues
adolescent animals (PND 48) have an overall lower TSPO protein and
gene expression than adult animals (PND 91), and that HU210
appears to cause a decrease in adult testicular TSPO expression while
adolescent testicular tissue appears to be unresponsive. TSPO is
thought to be involved in the rate limiting step of steroidogenesis
[4,5,19]. The observed age-related difference in testicular TSPO
expression is thus consistent with age-related changes in androgen
production associated with development into adulthood. Male rats do
not produce mature sperm until PND 53, an indication of sexual
maturity, and gradual increases in testosterone are only seen from
PND 45-56 [45]. Therefore, when adolescent animals were sacrificed
on PND 48, testosterone production and TSPO expression had yet to
reach its peak. Separately, results indicated that testicular and liver
binding affinity of 3H-PK11195 altered with age, although the
significance of this finding is unclear and requires further
investigation. Neither the kidney nor spleen tissues demonstrated any
age-related changes. These results, with the exception of alterations in
affinity, are consistent with previously reported age-related changes in
TSPO expression [46,47].
Both, radioligand membrane binding and RT-qPCR, reveal that
chronic high-dose administration of synthetic cannabinoid HU210
causes a decrease in testicular TSPO protein and mRNA expression in
adult but not adolescent animals. In addition, decreases in TSPO
expression appear to occur evenly throughout the testes as indicated
by an even autoradiographic spatial distribution pattern. The
expression of TSPO as seen in autoradiography is commensurate with
the fact that it is primarily expressed in the interstitial space between
the seminiferous tubules and is not expressed in the spermatids or
sperm [48]. Cannabinoid administration has previously been shown to
reduce adult testosterone production and levels [27] possibly through
the inhibition of cholesterol esterase and calcium transport through
calcium ATPase [31,32]. Given that TSPO is involved in
steroidogenesis and hence androgen production, the finding that
TSPO expression is decreased in response to HU210 administration
indicates that modulation of TSPO may be another possible
mechanism by which cannabinoids alter testosterone production. One
hypothesis is that testosterone production decreases in response to
cannabinoids due to decreases in TSPO facilitated cholesterol
transport across the mitochondrial membranes. Although testosterone
levels were not directly measured in the present study, previous studies
report alterations in testosterone levels and related functions following
similar, if not lower, doses of cannabinoids [30,32,49]. At present the
exact physiological effects of reduced TSPO expression in response to
HU210 administration is unknown and warrants further study,
particularly in regard to potential alterations to spermatogenesis and
sperm health [50,51]. A recent study in conditional TSPO knock-out
mice casts doubt on the assumption that the TSPO alone is essential
for testosterone production in Leydig cells [52]. The regulatory effect
of TSPO in testicular tissue may thus be more indirect than currently
thought and more closely related to the other roles of the TSPO, such
as cell cycle and cell metabolism than steroid biosynthesis per se
[53,54].
Unlike adult animals, HU210 did not alter testicular TSPO protein
density or distribution, or mRNA levels in adolescent animals. This
suggests a decreased vulnerability to cannabinoids or the presence of
other adaptive mechanisms. Previous studies using similar doses and
treatment regimens of HU210 as the present study have reported
alterations in various brain neurotransmitter systems in adult but not
adolescent animals [39-42]. The reasons why adolescent animals
appear to be less sensitive to cannabinoids, as observed in this study
and previous studies, remains unclear. Adolescent animals find
cannabinoids less aversive than adults in place and taste aversion tests
and emit less vocalisations in response to cannabinoid administration
[38] but cannabinoids have greater long-term behavioural detrimental
effects to adolescent animals [36-38]. It is possible that the reduced
aversion and sensitivity to cannabinoids results in a greater rate of
long-term effects. Similar observations have been reported with
alcohol, which have found that during adolescence alcohol may
interact with reward neurocircuitry and corticolimbic structure and
functions to promote maladaptive behaviours leading to addiction
[55]. Physiologically, a failure to regulate biochemical receptor
systems, including TSPO expression, could potentially increase the
susceptibility of adolescent animals to the long-term detrimental
effects of cannabinoids.
HU210 at doses similar to the ones used in the present study, have
previously been reported to produce anxiogenic responses in a variety
of tests, including the defensive withdrawal test [56] and the X-maze
[57]. Further, HU210 produces a persistent enhancement of emotional
responses to novel environments following withdrawal [57]. In animal
models, chronic stress such as inescapable shock and swim stress alters
TSPO expression in a variety of organs, in particular the kidney
[58-60], while in humans, anxiety disorders including generalized
anxiety disorder, panic disorder and post-traumatic stress disorder
alters TSPO expression in various blood cells including platelets and
monocytes [61-63]. To assess whether the anxiogenic properties of
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HU210 produced changes in TSPO expression similar to that of
chronic stress or anxiety disorders, we examined the spleen as it is
known to contain a large reservoir of platelets and monocytes [64,65],
the kidney and liver tissues. The results reveal no significant changes
in TSPO expression following HU210 administration in either adult or
adolescent animals in the kidney, spleen or liver. This was particular
surprising given the significant decreases in body weight gain, a
response normally associated with stress, in HU210 treated adult and
adolescent animals [66]. However, HU210 induced weight loss may be
accounted for by the activation of the CB1 receptor system which is
linked with the regulation of appetite, energy balance and metabolism
[67,68]. The published literature and our own data suggest that the
tissue-specific transcriptional regulation of TSPO is dependent on the
stressor used. Therefore, additional studies are required to clarify the
relationship between cannabinoids, anxiety and TSPO expression. In
summary, this study demonstrates that chronic administration of
HU210 alters TSPO expression in an age-specific manner by reducing
adult but not adolescent testicular TSPO expression.
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